Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNG100 in moderate atopic dermatitis
NCT04615962Phase 1Unknown
- Sponsor
- Seanergy Dermatology Ltd.
- Start
- Jan 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of SNG100 in atopic dermatitis (AD) (3 arms), sponsored by Seanergy Dermatology Ltd. Primary endpoint: Side Effects AE's and SAE's at 4 weeks. Status: unknown.
02
Drugs
SNG100
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04615962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04615962.